PRABOTULINUM TOXIN TYPE A

PRABOTULINUM TOXIN TYPE A was reported 3779 times

PRABOTULINUM TOXIN TYPE A is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 VIRAL CORNEAL ULCER 1 0.0909
1 BIOPSY UTERUS ABNORMAL 1 0.0769
2 PATIENT DISSATISFACTION WITH TREATMENT 105 0.0544
3 ALLERGY TEST 1 0.0526
4 LID LAG 3 0.0429
5 DRUG EFFECT LESS THAN EXPECTED 469 0.0316
6 MEPHISTO SIGN 2 0.0282
7 BROW PTOSIS 14 0.0213
8 REDUCED FACIAL EXPRESSION 17 0.0167
9 THERAPEUTIC PRODUCT EFFECT DECREASED 715 0.0159
10 DERMATOCHALASIS 2 0.0136
11 ADMINISTRATION SITE WARMTH 1 0.0122
12 PROGNATHISM 1 0.0106
13 FACIAL ASYMMETRY 10 0.0105
14 PRODUCT PREPARATION ISSUE 59 0.0090
15 EYELID PTOSIS 73 0.0072
16 EAR, NOSE AND THROAT DISORDER 1 0.0071
17 INJECTION SITE PAPULE 28 0.0061
18 EUSTACHIAN TUBE OBSTRUCTION 1 0.0061
19 INJECTION SITE PUSTULE 2 0.0052
20 INJECTION SITE ECZEMA 1 0.0052
21 EXTRAOCULAR MUSCLE PARESIS 2 0.0044
22 SKIN INDENTATION 2 0.0042
23 INJECTION SITE GRANULOMA 1 0.0042
24 APPLICATION SITE ACNE 2 0.0041
25 FACIAL NEURALGIA 1 0.0038
26 CONJUNCTIVITIS VIRAL 1 0.0038
27 PERIORBITAL SWELLING 20 0.0035
28 INJECTION SITE OEDEMA 6 0.0035
29 MUSCLE HYPERTROPHY 1 0.0028
30 NEUROMUSCULAR TOXICITY 1 0.0028
31 FACIAL DISCOMFORT 2 0.0028
32 INJECTION SITE HYPOAESTHESIA 4 0.0028
33 NASAL TURBINATE HYPERTROPHY 1 0.0027
34 THERAPEUTIC RESPONSE DELAYED 7 0.0025
35 SKIN LAXITY 1 0.0023
36 FACIAL NERVE DISORDER 1 0.0023
37 SKIN WRINKLING 6 0.0022
38 MASTOCYTOSIS 1 0.0021
39 CRANIAL NERVE PARALYSIS 1 0.0021
40 INJECTION SITE INFLAMMATION 10 0.0020
41 SWELLING OF EYELID 12 0.0019
42 OCCIPITAL NEURALGIA 1 0.0018
43 SOFT TISSUE SWELLING 1 0.0018
44 THERAPEUTIC PRODUCT EFFECT DELAYED 8 0.0018
45 OFF LABEL USE 1315 0.0015
46 INJECTION SITE PARAESTHESIA 2 0.0013
47 INJECTION SITE SWELLING 99 0.0013
48 EYELID FUNCTION DISORDER 1 0.0013
49 PHARYNGEAL PARAESTHESIA 2 0.0013
50 DRUG INEFFECTIVE 1590 0.0012
51 EYELID IRRITATION 3 0.0012
52 PERIORBITAL PAIN 1 0.0012
53 ENDOCRINE OPHTHALMOPATHY 1 0.0012
54 CERUMEN IMPACTION 1 0.0011
55 BIOPSY 1 0.0011
56 INJECTION SITE ULCER 1 0.0011
57 APPLICATION SITE BRUISE 1 0.0010
58 EYELID RASH 1 0.0010
59 EYELIDS PRURITUS 3 0.0010
60 INJECTION SITE HYPERSENSITIVITY 3 0.0010
61 EYE CONTUSION 2 0.0009
62 INJECTION SITE IRRITATION 12 0.0009
63 EYELID DISORDER 2 0.0009
64 THERAPEUTIC PRODUCT EFFECT INCREASED 1 0.0009
65 SINUS PAIN 2 0.0009
66 INJECTION SITE DISCOMFORT 9 0.0009
67 INJECTION SITE VESICLES 5 0.0008
68 INJECTION SITE PRURITUS 52 0.0008
69 DACRYOSTENOSIS ACQUIRED 1 0.0008
70 COUNTERFEIT PRODUCT ADMINISTERED 1 0.0008
71 LIP EXFOLIATION 1 0.0008
72 POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME 1 0.0007
73 OFF LABEL USE OF DEVICE 1 0.0007
74 MUSCLE TWITCHING 17 0.0007
75 LIP PAIN 2 0.0007
76 EYELID OEDEMA 8 0.0007
77 ACNE CYSTIC 2 0.0007
78 INJECTION SITE NODULE 7 0.0006
79 OPHTHALMOPLEGIA 1 0.0006
80 MEDICAL PROCEDURE 1 0.0006
81 LOWER RESPIRATORY TRACT CONGESTION 1 0.0006
82 PRODUCT TEMPERATURE EXCURSION ISSUE 3 0.0006
83 PRODUCT CONTAINER SEAL ISSUE 1 0.0006
84 VERTIGO POSITIONAL 1 0.0006
85 SKIN HYPOPIGMENTATION 1 0.0006
86 FACIAL PAIN 5 0.0006
87 TETANY 1 0.0005
88 ASTHENOPIA 3 0.0005
89 INJECTION SITE MASS 20 0.0005
90 INJECTION SITE ERYTHEMA 67 0.0005
91 LIP DISORDER 1 0.0005
92 DIPLOPIA 13 0.0005
93 CARDIAC DISCOMFORT 1 0.0005
94 EYELID PAIN 1 0.0005
95 BLEPHAROSPASM 3 0.0005
96 INJECTION SITE INDENTATION 1 0.0005
97 EYE SWELLING 17 0.0005
98 INJECTION SITE RASH 14 0.0005
99 PRODUCT STORAGE ERROR 39 0.0004
100 VITILIGO 1 0.0004
101 PAPULE 3 0.0004
102 SKIN TIGHTNESS 2 0.0004
103 BREATH ODOUR 1 0.0004
104 EYE OEDEMA 1 0.0004
105 INJECTION SITE DISCOLOURATION 5 0.0004
106 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 72 0.0004
107 OSTEITIS 1 0.0004
108 LABYRINTHITIS 1 0.0004
109 PERIORBITAL OEDEMA 2 0.0004
110 EXFOLIATIVE RASH 1 0.0004
111 INJECTION SITE PAIN 114 0.0004
112 MIGRAINE WITH AURA 1 0.0004
113 VERTIGO 22 0.0004
114 ELECTRIC SHOCK SENSATION 1 0.0004
115 FACIAL PARALYSIS 3 0.0004
116 HYPOAESTHESIA ORAL 5 0.0003
117 KERATITIS 1 0.0003
118 VISION BLURRED 43 0.0003
119 SWELLING FACE 20 0.0003
120 DEAFNESS NEUROSENSORY 1 0.0003
121 NEAR DEATH EXPERIENCE 1 0.0003
122 WRONG PRODUCT ADMINISTERED 2 0.0003
123 INJECTION SITE WARMTH 6 0.0003
124 FACIAL PARESIS 1 0.0003
125 HEAD DISCOMFORT 5 0.0003
126 PARAESTHESIA ORAL 4 0.0003
127 PANIC REACTION 2 0.0003
128 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 15 0.0003
129 HEADACHE 171 0.0003
130 OCULAR DISCOMFORT 3 0.0003
131 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 19 0.0003
132 PHOTOPHOBIA 5 0.0003
133 LACRIMATION INCREASED 8 0.0003
134 PARANASAL SINUS DISCOMFORT 1 0.0003
135 CONJUNCTIVAL HAEMORRHAGE 1 0.0003
136 THERAPEUTIC PRODUCT EFFECT VARIABLE 1 0.0003
137 BRAIN FOG 4 0.0003
138 SUSPECTED COUNTERFEIT PRODUCT 1 0.0003
139 EXPOSURE VIA BREAST MILK 1 0.0003
140 SKIN PAPILLOMA 1 0.0002
141 MUSCLE TIGHTNESS 4 0.0002
142 SWELLING 23 0.0002
143 SENSATION OF FOREIGN BODY 2 0.0002
144 TEARFULNESS 1 0.0002
145 HORDEOLUM 1 0.0002
146 INJECTION SITE BRUISING 18 0.0002
147 OROPHARYNGEAL DISCOMFORT 2 0.0002
148 DRY EYE 11 0.0002
149 DEFORMITY 2 0.0002
150 PAIN IN JAW 6 0.0002
151 INJECTION SITE URTICARIA 5 0.0002
152 VITREOUS FLOATERS 2 0.0002
153 DYSPHAGIA 19 0.0002
154 BURNING SENSATION 14 0.0002
155 TRISMUS 1 0.0002
156 TENDERNESS 2 0.0002
157 CHEILITIS 1 0.0002
158 ERYTHEMA OF EYELID 1 0.0002
159 NONSPECIFIC REACTION 1 0.0002
160 CHOKING SENSATION 1 0.0002
161 MULTIPLE USE OF SINGLE-USE PRODUCT 1 0.0002
162 SKIN WARM 1 0.0002
163 CATARACT OPERATION 1 0.0002
164 NASAL DRYNESS 1 0.0002
165 INTRAOCULAR PRESSURE INCREASED 2 0.0002
166 APPLICATION SITE VESICLES 1 0.0002
167 EYE DISORDER 5 0.0002
168 ADVERSE REACTION 2 0.0002
169 SKIN MASS 1 0.0001
170 SINUS CONGESTION 2 0.0001
171 THROAT TIGHTNESS 4 0.0001
172 DISCOMFORT 9 0.0001
173 GENERAL PHYSICAL CONDITION ABNORMAL 1 0.0001
174 ACCIDENTAL EXPOSURE TO PRODUCT BY CHILD 1 0.0001
175 EYE MOVEMENT DISORDER 1 0.0001
176 PRODUCT PREPARATION ERROR 3 0.0001
177 DROOLING 1 0.0001
178 MUSCULAR WEAKNESS 16 0.0001
179 HYPOAESTHESIA 21 0.0001
180 SENSITIVE SKIN 1 0.0001
181 CONTUSION 13 0.0001
182 URINARY INCONTINENCE 4 0.0001
183 DISSOCIATION 1 0.0001
184 APHTHOUS ULCER 1 0.0001
185 OCULAR HYPERAEMIA 6 0.0001
186 GINGIVAL PAIN 1 0.0001
187 MUSCLE DISORDER 1 0.0001
188 PRESYNCOPE 3 0.0001
189 HYPERAESTHESIA 1 0.0001
190 UPPER-AIRWAY COUGH SYNDROME 1 0.0001
191 PHOTOSENSITIVITY REACTION 2 0.0001
192 LIP SWELLING 4 0.0001
193 PALPITATIONS 14 0.0001
194 INCORRECT ROUTE OF PRODUCT ADMINISTRATION 2 0.0001
195 SPEECH DISORDER 6 0.0001
196 GRIP STRENGTH DECREASED 1 0.0001
197 DRY MOUTH 9 0.0001
198 TOOTHACHE 2 0.0001
199 PANIC ATTACK 4 0.0001
200 INFLUENZA LIKE ILLNESS 9 0.0001
201 TINNITUS 5 0.0001
202 HYPERSENSITIVITY 20 0.0001
203 EYE PAIN 6 0.0001
204 AUTOIMMUNE DISORDER 1 0.0001
205 ERYTHEMA 21 0.0001
206 SALIVARY HYPERSECRETION 1 0.0001
207 FEELING HOT 6 0.0001
208 EAR DISCOMFORT 1 0.0001
209 TEMPERATURE INTOLERANCE 1 0.0001
210 PETECHIAE 1 0.0001
211 ASPIRATION 1 0.0001
212 DIZZINESS 45 0.0001
213 NERVE INJURY 1 0.0001
214 EYE PRURITUS 3 0.0001
215 PARAESTHESIA 14 0.0001
216 HEART RATE IRREGULAR 2 0.0001
217 INJECTION SITE REACTION 6 0.0001
218 DYSPHONIA 5 0.0001
219 MIGRAINE 8 0.0001
220 UNDERDOSE 6 0.0001
221 DERMATITIS ALLERGIC 1 0.0001
222 MUSCLE ATROPHY 1 0.0001
223 PRODUCT COMPLAINT 2 0.0001
224 MYDRIASIS 1 0.0001
225 URTICARIA 13 0.0001
226 INJECTION SITE INDURATION 1 0.0001
227 ANAPHYLACTIC REACTION 4 0.0001
228 MASS 1 0.0001
229 BLINDNESS UNILATERAL 1 0.0001
230 EYE IRRITATION 4 0.0001
231 HYPOKINESIA 1 0.0001
232 THERAPEUTIC RESPONSE DECREASED 4 0.0001
233 UPPER RESPIRATORY TRACT INFECTION 3 0.0001
234 VISUAL IMPAIRMENT 8 0.0001
235 SWOLLEN TONGUE 2 0.0001
236 PRODUCT USE COMPLAINT 1 0.0001
237 SENSORY DISTURBANCE 1 0.0001
238 GENERALISED TONIC-CLONIC SEIZURE 1 0.0001
239 THERAPEUTIC RESPONSE SHORTENED 2 0.0001
240 PRURITUS 23 0.0001
241 FACE OEDEMA 1 0.0001
242 SCAR 1 0.0001
243 LYMPHADENOPATHY 2 0.0001
244 THIRST 1 0.0001
245 PRODUCT ADMINISTERED AT INAPPROPRIATE SITE 1 0.0001
246 BLOOD GLUCOSE ABNORMAL 1 0.0001
247 CONJUNCTIVITIS 1 0.0001
248 UNEVALUABLE EVENT 4 0.0001
249 RASH 23 0.0001
250 POST PROCEDURAL COMPLICATION 1 0.0001
251 ORAL HERPES 1 0.0001
252 NASAL CONGESTION 3 0.0001
253 SINUS DISORDER 1 0.0001
254 HEART RATE INCREASED 5 0.0001
255 SYNCOPE 5 0.0000
256 TASTE DISORDER 1 0.0000
257 FLUSHING 5 0.0000
258 MUSCLE SPASMS 9 0.0000
259 MUSCULOSKELETAL STIFFNESS 4 0.0000
260 TACHYCARDIA 4 0.0000
261 ORAL PAIN 1 0.0000
262 THROAT IRRITATION 2 0.0000
263 PANCREATITIS ACUTE 1 0.0000
264 SKIN DISCOLOURATION 2 0.0000
265 ANXIETY 12 0.0000
266 PRODUCTIVE COUGH 2 0.0000
267 RASH ERYTHEMATOUS 2 0.0000
268 FEELING ABNORMAL 10 0.0000
269 AGEUSIA 1 0.0000
270 ANAPHYLACTIC SHOCK 1 0.0000
271 JOINT STIFFNESS 1 0.0000
272 PAIN 23 0.0000
273 DYSPNOEA 21 0.0000
274 DISTURBANCE IN ATTENTION 2 0.0000
275 LIMB INJURY 1 0.0000
276 PALLOR 1 0.0000
277 SKIN LESION 1 0.0000
278 HERPES ZOSTER 2 0.0000
279 INTENTIONAL PRODUCT MISUSE 3 0.0000
280 RESPIRATORY DISORDER 1 0.0000
281 CHEST PAIN 6 0.0000
282 LIMB DISCOMFORT 1 0.0000
283 PRODUCT USE IN UNAPPROVED INDICATION 8 0.0000
284 EXPOSURE DURING PREGNANCY 2 0.0000
285 RHINORRHOEA 2 0.0000
286 TREMOR 5 0.0000
287 SKIN DISORDER 1 0.0000
288 SINUSITIS 3 0.0000
289 ASTHENIA 11 0.0000
290 HEART RATE DECREASED 1 0.0000
291 RESTLESSNESS 1 0.0000
292 AGITATION 2 0.0000
293 DYSARTHRIA 1 0.0000
294 WHITE BLOOD CELL COUNT INCREASED 1 0.0000
295 SEIZURE 3 0.0000
296 INJECTION SITE HAEMORRHAGE 2 0.0000
297 NAUSEA 19 0.0000
298 ANGIOEDEMA 1 0.0000
299 THERAPY NON-RESPONDER 1 0.0000
300 ADVERSE EVENT 2 0.0000
301 ARTHRALGIA 9 0.0000
302 OROPHARYNGEAL PAIN 2 0.0000
303 BLOOD GLUCOSE DECREASED 1 0.0000
304 MALAISE 9 0.0000
305 DYSPEPSIA 2 0.0000
306 FLUID RETENTION 1 0.0000
307 CHEST DISCOMFORT 2 0.0000
308 NERVOUSNESS 1 0.0000
309 ECZEMA 1 0.0000
310 MUSCULOSKELETAL PAIN 1 0.0000
311 RASH PRURITIC 1 0.0000
312 OEDEMA 1 0.0000
313 NECK PAIN 1 0.0000
314 BLISTER 1 0.0000
315 CHILLS 2 0.0000
316 SURGERY 1 0.0000
317 FATIGUE 13 0.0000
318 STOMATITIS 1 0.0000
319 PRODUCT USE ISSUE 3 0.0000
320 GAIT DISTURBANCE 3 0.0000
321 LOSS OF CONSCIOUSNESS 2 0.0000
322 HYPERHIDROSIS 2 0.0000
323 PRODUCT QUALITY ISSUE 2 0.0000
324 MEMORY IMPAIRMENT 2 0.0000
325 PYREXIA 5 0.0000
326 SLEEP DISORDER 1 0.0000
327 HYPERTENSION 3 0.0000
328 SKIN BURNING SENSATION 1 0.0000
329 PERIPHERAL SWELLING 2 0.0000
330 FALL 4 0.0000
331 ABDOMINAL DISCOMFORT 2 0.0000
332 CEREBROVASCULAR ACCIDENT 2 0.0000
333 BALANCE DISORDER 1 0.0000
334 ADVERSE DRUG REACTION 1 0.0000
335 COUGH 3 0.0000
336 ATRIAL FIBRILLATION 1 0.0000
337 ALOPECIA 2 0.0000
338 HAEMORRHAGE 1 0.0000
339 CONSTIPATION 2 0.0000
340 ASTHMA 1 0.0000
341 RHEUMATOID ARTHRITIS 1 0.0000
342 INCORRECT DOSE ADMINISTERED 2 0.0000
343 GENERAL PHYSICAL HEALTH DETERIORATION 1 0.0000
344 BACK PAIN 2 0.0000
345 VOMITING 4 0.0000
346 JOINT SWELLING 1 0.0000
347 EMOTIONAL DISTRESS 1 0.0000
348 INSOMNIA 2 0.0000
349 WEIGHT DECREASED 2 0.0000
350 INFECTION 1 0.0000
351 BLOOD PRESSURE INCREASED 1 0.0000
352 CONFUSIONAL STATE 1 0.0000
353 MYALGIA 1 0.0000
354 URINARY TRACT INFECTION 1 0.0000
355 MYOCARDIAL INFARCTION 1 0.0000
356 NO ADVERSE EVENT 1 0.0000
357 NASOPHARYNGITIS 1 0.0000
358 HYPOTENSION 1 0.0000
359 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 1 0.0000
360 ABDOMINAL PAIN UPPER 1 0.0000
361 DEPRESSION 1 0.0000
362 DECREASED APPETITE 1 0.0000
363 ABDOMINAL PAIN 1 0.0000
364 CONDITION AGGRAVATED 1 0.0000
365 DIARRHOEA 2 0.0000
366 PNEUMONIA 1 0.0000